Solanezumab is a humanized monoclonal IgG1 antibody which is directed against the mid-domain of the Aβ peptide. By sequestering Aβ, shifting equilibria between different species of Aβ, and removing small soluble species of Aβ that are directly toxic to synaptic function, it may exert benefit.
Peptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C6396H9922N1712O1996S42 |
M.W/Mr. | 144000.1g/mol |
Labeling Target | Amyloid precursor protein (APP) |
Application | Solanezumab, or sola, binds the amyloid-β peptides that aggregate and form plaques in the brain that are an early pathological feature of Alzheimer's disease. |
Areas of Interest | Neurological Disease |
4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
5. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.